CASE REPORTS
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Aspergillus chevalieri (Mangin) Thom and Church: a new opportunistic pathogen of human cutaneous aspergillosis.

Mycoses 1994
Three cases of opportunistic cutaneous aspergillosis caused by Aspergillus chevalieri are described. The lesions were erythematous and hyperkeratotic with vesicopapular eruptions and scaling. Histopathology revealed granulomatous reaction showing polymorphonuclear leucocytes around fungal hyphae, which were broad, septate, branched and aggregated in the epidermal area. Oxiconazole and amorolfine, with a minimum inhibitory concentration of 10 micrograms ml-1, were the most active drugs against A. chevalieri 'in vitro'. A. chevalieri is, for the first time, documented as opportunistic pathogen of man.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app